WSL
ORKA

Western Standard LLC’s Oruka Therapeutics ORKA Stock Holding History

Western Standard LLC’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-117,512
Closed -$2.48M – 30
2024
Q1 		$2.48M Hold
117,512
– – 1.19% 14
2023
Q4 		$2.4M Buy
117,512
+19,656
+20% +$441K 1.6% 13
2023
Q3 		$2.36M Buy
97,856
+45,340
+86% +$1.11M 2.13% 14
2023
Q2 		$1.28M Buy
+52,516
New +$1.29M 1.1% 16

Other funds holding ORKA

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Western Standard LLC's ORKA Position: Q2 2024 in Review

Western Standard LLC sold out of Oruka Therapeutics (ORKA) in Q2 2024, closing a stake of 117,512 shares — an estimated $2.48M sold.

Western Standard LLC first reported a position in ORKA in Q2 2023 and held it in 4 quarters. The position peaked at $2.48M in Q1 2024. 31 funds tracked by Wall St. Rank hold ORKA as of Q2 2024.

  • Western Standard LLC reported no remaining Oruka Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Western Standard LLC sold 117,512 Oruka Therapeutics shares in Q2 2024, an estimated $2.48M.
  • Western Standard LLC first reported a position in Oruka Therapeutics in Q2 2023 and held it in 4 quarters.
  • Western Standard LLC's Oruka Therapeutics position peaked at $2.48M in Q1 2024.
  • 31 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2024.

Based on Western Standard LLC's 13F filing for Q2 2024, filed 14 Aug 2024.